Bristol Myers Squibb announced a partnership with Chinese drugmaker Hengrui Pharma covering more than a dozen early-stage programs, according to STAT News. The deal is among the largest examples of a global pharmaceutical company turning to China to restock its early-stage pipeline, STAT reported.